Benign flesh-colored, pink, and red skin growths


Lichen simplex chronicus

Clinical features

Lichen simplex chronicus (LSC; also known as “neurodermatitis”) is a common secondary skin condition characterized by the development of thickened plaques with accentuated skin lines (i.e., lichenification).

  • LSC is caused by chronic scratching or rubbing.

    • Patients do not always report frequent rubbing or scratching of the affected area.

  • Plaques are typically well demarcated but can take on irregular, ovular, or angular morphologies and can vary in size.

    • Concomitant excoriations are frequently present.

    • Newly formed plaques are usually characterized by separate zones.

      • The peripheral zone (2–3 cm) is defined by marginal skin thickening, often with discrete papules.

      • The central zone has greater degrees of skin thickening and exaggerated skin lines.

      • Secondary pigmentation changes may be more dramatic in individuals with darker skin.

        • Plaques may be hyperpigmented or hypopigmented, depending on chronicity.

  • LSC most commonly affects areas that are accessible to scratching, such as the scalp, legs, neck, genitals ( Fig. 11.1 ), arms, and face.

    • It is more common on the patient’s dominant side.

    • Unlike prurigo nodularis, LSC typically presents with one to five plaques, although in some cases many lesions are present.

    • Although LSC can be seen in all age groups, it is distributed bimodally, peaking in childhood and then again in mid to late adulthood.

    • LSC is more common in women than in men.

    Fig. 11.1, Lichen Simplex Chronicus, Scrotum.

LSC can either arise in areas affected by a different primary dermatosis (e.g., atopic dermatitis [AD]) or de novo from idiopathic pruritus.

  • In some cases of de novo LSC, it is thought to arise as a manifestation of an underlying psychiatric condition (e.g., generalized anxiety disorder, obsessive compulsive disorder [OCD]).

Differential diagnosis

The differential for LSC includes squamous cell carcinoma (SCC), lichen sclerosus, prurigo nodularis, lichen planus (LP), and psoriasis. Importantly, lichenification can arise secondary to a number of pruritic skin conditions. In all cases, it is important to recognize that patients may have a separate, underlying primary skin condition (including those in the differential diagnosis).

  • SCC can also present as an isolated hyperkeratotic plaque. SCC is always in the differential for LSC. Cases of suspected LSC that demonstrate no response to occluded, super-potent topical corticosteroids or intralesional corticosteroids should be biopsied to rule out SCC. Importantly, this biopsy should be interpreted by a dermatopathologist because reaction changes seen in LSC can mimic SCC.

  • Genital LSC can be confused with lichen sclerosus. Unlike LSC, which presents with thickened skin, lichen sclerosus presents with atrophic white plaques that burn in a perigenital distribution. The appearance of lichen sclerosus has been likened to that of cigarette paper. Untreated lichen sclerosus can cause genital disfigurement and can lead to development of SCC.

  • Prurigo nodules are similar to LSC; however, they are nodular and frequently more widespread. Both conditions are caused by chronic scratching, rubbing, or picking.

  • Hypertrophic LP can present with hyperkeratotic plaques, typically affecting the shins. It can be differentiated from LSC because hypertrophic LP typically presents with multiple lesions and typical LP lesions may be identifiable elsewhere.

  • Other chronic inflammatory conditions (e.g., AD, psoriasis) can mimic LSC and can develop secondary lichenification from chronic scratching. In these cases, a primary dermatosis is also identified.

Work-up

LSC can typically be diagnosed clinically; however, histopathologic confirmation is occasionally necessary.

The presence of an isolated, lichenified plaque with accentuated skin lines and dyspigmentation is suggestive of a diagnosis of LSC.

  • This is further supported by a patient history of repetitive scratching to the affected regions; however, many patients deny scratching.

  • Visualization of broken hairs or excoriations may support a diagnosis of LSC because they are signs of chronic scratching.

  • The presence of a primary dermatosis does not in and of itself rule out a diagnosis of LSC.

Patients who do not respond as expected to a 4-week course of occluded, super-potent topical corticosteroids or intralesional corticosteroids should undergo biopsy to rule out more significant pathology.

Initial steps in management

General management comments

Management of LSC differs based on whether or not the patient has an underlying primary dermatosis.

  • If a primary dermatosis is present, treatment should initially be directed at managing the underlying condition.

  • If there is no primary dermatosis, LSC-directed management should ensue.

    • Some providers screen for the presence of comorbid psychiatric illness in patients with LSC and refer appropriately based on the results of screening.

Recommended initial treatment

Patients should be treated with either potent topical corticosteroids under occlusion or intralesional corticosteroids.

  • For nonfacial, nongenital lesions, class I corticosteroids (e.g., clobetasol propionate 0.05%) can be occluded under saran wrap daily for 2 to 4 weeks.

  • For facial or genital lesions, a 2-week trial of a nonoccluded mid-potency corticosteroid (e.g., triamcinolone acetonide 0.1% cream) twice daily can be trialed.

  • Intralesional corticosteroids (e.g., triamcinolone acetonide 10 mg/kg for nonfacial, nongenital skin; triamcinolone acetonide 5 mg/kg for facial or genital skin) can be performed and repeated at 4-week intervals as needed.

  • Intralesional corticosteroids are highly effective for solitary lesions but should only be performed by an experienced healthcare provider because they can result in significant local AEs if injected inappropriately.

  • Patients should also be advised to keep lesions covered with bandages and to apply a thick moisturizer (e.g., zinc oxide barrier cream) to the affected area every time that it itches. This is frequently helpful with breaking the itch-scratch cycle that drives this condition.

Partial but inadequate response

If there is a partial but inadequate response after a trial of topical or intralesional corticosteroids, confirm the diagnosis, if it is in question, with a biopsy. Then add systemic anti-itch medications (e.g., gabapentin, pregabalin, n-acetylcysteine) or consider referral to a dermatologist.

  • A punch biopsy is frequently required to obtain a sample of the entirety of the epidermis.

  • You can also assess for patient willingness to seek cognitive behavioral therapy/psychiatrist evaluation to help break the itch-scratch cycle if an underlying psychiatric condition is suspected or known.

Warning signs/common pitfalls

SCC can mimic LSC and can develop concomitantly in patients with known LSC. If suspected LSC continues to grow despite treatment, a biopsy is always indicated.

Antihistamines and oral corticosteroids are frequently prescribed for the treatment of LSC but are unlikely to offer the patient any benefit.

A major pitfall in the treatment of LSC is failure to identify the primary driver of the patient’s scratch–itch cycle.

  • Failing to adequately address a mental health disorder that may be leading to LSC impedes treatment success.

    • In patients with OCD, significant depression, or anxiety, treatment success involves a multispecialty approach that may involve a psychiatrist, counselor, and primary care physician.

  • Similarly, if the patient’s pruritus is driven by a primary skin condition, such as psoriasis or AD, it is essential to adequately treat the primary condition.

LSC can become superinfected. Skin lesions demonstrating signs of warmth, erythema, or discharge should be cultured and treated with either a topical or oral antibiotic.

Counseling

You have a condition called “lichen simplex chronicus.” This type of rash is usually caused by excessive scratching or rubbing of the same area of skin over time. This condition is frequently difficult to treat.

There are several things you should do to treat your rash. First, you have been prescribed a topical corticosteroid. Apply this to the affected area and then wrap the area with saran wrap to help get the medicine into the skin. If this is not feasible, apply a bandage over the prescription cream. Second, keep the area covered with a bandage at all times, even when you sleep. Lastly, apply a thick moisturizing cream to the area every time that it itches as many times as is necessary throughout the day.

If your rash fails to improve despite this therapy, we will re-evaluate it.

Keloids

Shivani Sinha, Gloria Lin, and Katalin Ferenczi

Clinical features

Keloids are characterized by an excessive growth of scar tissue in response to dermal injury; rarely, they have been reported to present spontaneously in patients prone to developing keloids. They are more commonly seen in younger, darker-skinned individuals, who may be genetically predisposed to developing these lesions. Their cosmetically disfiguring nature and lack of efficacious therapies can make this a challenging diagnosis because patients may be disappointed with the treatment outcomes.

  • Given the prevalence of keloids, patients often self-diagnose this condition without the aid of a medical professional. They will complain of pruritus, tenderness, and enlargement of the lesions while relating a history of inciting cutaneous injury, including piercings, surgeries, vaccinations, burns, and acne.

  • Keloids appear as smooth, shiny, flesh-colored to pink or red or hyperpigmented papules, plaques, or nodules, which are usually firm, rubbery, and can be pruritic or painful. They may present anywhere on the body but are often seen on the earlobes, chest, and back. The keloids may not appear until months after the cutaneous insult. Without intervention, progressive enlargement is possible because they are unlikely to regress on their own. Keloids may produce contractures, causing impaired function, which can be debilitating for the patient.

Differential diagnosis

The differential diagnosis for keloids include hypertrophic scars, dermatofibromas (DFs), dermatofibrosarcoma protuberans (DFSP), foreign body reaction, sarcoidosis, keloidal scleroderma, and lobomycosis.

  • Hypertrophic scars are large, thickened scars that are confined to the wound borders, whereas keloids extend beyond it. They tend to appear quickly after the preceding trauma and can resolve. Keloids, on the other hand, may appear months later and are unlikely to improve without treatment.

  • DFs are thought to arise in areas of trauma (i.e., shaving or arthropod bites) and are commonly seen in young females on the lower extremities, upper arms, and upper back. They present as firm, skin-colored or hyperpigmented papules or nodules, which can be pruritic or painful. On physical examination, DFs may have a positive dimple sign when squeezed because the skin will pucker inwards. Similar to keloids, these are unlikely to resolve on their own.

  • DFSP is a locally aggressive soft-tissue sarcoma seen on the trunk or proximal extremities. DFSP appears as a firm, slow-growing plaque that becomes large and protuberant over time. Although this is a malignant condition, lymphatic or hematogenous metastasis is rare. Patients suspected of having a DFSP should be referred to a dermatologist for further evaluation and possible biopsy because it may require treatment with wide excision, Mohs micrographic surgery, radiation, and/or imatinib.

  • A foreign body reaction may occur as a result of trauma and after implantation of foreign material in the skin and involves an inflammatory soft tissue response. It may appear as a painful, flesh-colored, erythematous, or hyperpigmented papule, nodule, or plaque at the site of injury. Referral to dermatology is recommended because the area may need to be biopsied or excised for diagnosis and therapy (to remove the foreign body).

  • Sarcoidosis can mimic keloids because it can also occur at areas of trauma, injury, or pre-existent scars. Clinically, it can form hyperpigmented nodules that may be confused with keloids. On examination, compression of the lesion with a glass slide (diascopy) can demonstrate an apple jelly like appearance that is often associated with granulomatous processes. A biopsy will demonstrate sarcoidal granulomas.

  • Keloidal scleroderma is a rare variant of scleroderma that presents with multiple hyperpigmented nodules or plaques that are localized to the upper trunk. Although these lesions clinically resemble keloids, they are nontender and lack a history of an inciting injury and the systemic symptoms that may be seen with scleroderma.

  • Lobomycosis, also known as “keloidal blastomycosis,” is a fungal infection usually seen in more tropical areas, such as Central or South America. Chronic infection leads to the formation of nodules and plaques, whose growth and appearance resemble keloids. Treatment can be challenging, especially if there is widespread disease. A biopsy with special stains is often required to establish this diagnosis.

Work-up

This is usually a clinical diagnosis based on physical examination and history.

  • The shape of the scar, growth progression, family history, and antecedent skin injury may support a diagnosis of keloid.

  • If there is any uncertainty in the diagnosis, the patient should be referred to a dermatologist for further evaluation and treatment. A biopsy may be performed by a dermatologist to rule out serious skin conditions or malignancies that can mimic keloids.

Initial steps in management

The initial management of keloids is complex and often requires a combination of therapies. The most important step in management is to educate the patient on avoiding cutaneous injury and to discuss realistic treatment expectations.

  • Advise against any further insult to the skin, including piercings, elective surgeries, and burns. Caution should be taken when shaving to avoid any injury. If the patient has an active underlying condition, such as acne, this should be treated to prevent further keloid formation.

  • Recommend counseling the patient that the management goal is symptomatic relief (decrease pain and/or pruritus). There may be some aesthetic improvement; however, because there is scar tissue in the area, the skin cannot return to baseline. In addition, it is important to discuss that it will likely require multiple treatments to see maximum benefit. Many patients will often ask why the area cannot just be shaved down; thus it is important to discuss the high recurrence risk with this treatment method.

Management of keloids involves dividing cases by number, location, and size because this can affect the management plan. Based on the complexity and possible reactions to the treatments, a referral to dermatology is recommended.

Small or treatment-naïve keloids

  • Intralesional triamcinolone acetonide (10–40 mg/mL) can be administered once or twice monthly to reduce inflammation and halt the proliferative process. This treatment may be beneficial for fast-acting symptomatic relief. Keloids treated with intralesional steroids may become softer in texture over time, making it easier to administer injections at a later time. Patients should be counseled on the risk for atrophy and dyspigmentation. Given the variability in the dosing and treatment schedule, the patient should be referred to a dermatologist.

  • Occlusive silicone gel sheeting is used for both treatment and prophylaxis by providing hydration to the dermal layers.

  • Pressure therapy involves applying dressing or bandages to the affected area to reduce the growth of scar tissue. For keloids on the ears, pressure earrings can be used and are highly recommended postoperatively to reduce the risk for recurrence.

Larger or treatment-refractory keloids

  • Intralesional 5-fluorouracil (50 mg/mL) can be injected once weekly for up to 12 weeks to reduce inflammation. This option can be used in keloids that are unresponsive to steroid injections. Given the potential risk for side effects and need for biohazard precautions, the patient should be referred to a dermatologist.

  • Cryotherapy (liquid nitrogen) can be performed to decrease the size of the keloid. Patients should be counseled on the risk for dyspigmentation in the treatment area.

  • Laser therapy, including CO 2 , Nd:YAG, or PDL, can be used on enlarging lesions to halt the progressive growth of scar tissue.

  • Surgical excision of the keloid may be performed when the scar is large or linear, but the risks of the procedure should be clearly explained to the patient because the defect will likely be larger than the actual lesion, and the keloid can recur and worsen. For areas such as the ear, surgery may not be advisable because it can result in volume loss and asymmetry compared with the other side.

    • Many patients may not be ideal surgical candidates because it requires consistently following up with the healthcare provider. Further adjunctive therapy may be needed even after the procedure to decrease the risk for recurrence.

    • Intralesional steroids may be injected into the surgical site postoperatively on the same day and at subsequent follow-up visits.

    • Radiation therapy may also be used postoperatively to reduce the likelihood of recurrence after excision.

    • The patients may require multiple procedures to achieve the optimal outcome.

  • Other emerging therapies, such as dupilumab, an IL-4 receptor inhibitor, have shown some promise in this condition.

Warning signs/common pitfalls

  • Keloids are not malignant; however, there are nonbenign conditions that may visually resemble keloids. Patients should be referred to dermatology for possible biopsy and histologic examination to rule out malignancy if there is any doubt about the diagnosis.

  • Keloids present with a high recurrence rate after treatment. Scars will often require multiple rounds of combination therapy. Even with treatment, there may not be significant improvement with the appearance of the lesions.

  • Cosmetic disfigurement, functional limitation, and symptoms of pain and pruritus may cause decreased quality of life and should be addressed.

Counseling

You have a keloid, which is an overgrown scar. It should be evaluated by a dermatologist, who may perform a biopsy to confirm the diagnosis. The primary goal is to minimize any associated symptoms, such as pain and itching. It is important to note that the area will not revert back to normal skin even with treatment, but there could potentially be some improvement with the size and texture of the lesions. Treatment could include steroid injections into the scar to halt its growth and decrease the size. This can be done in combination with other forms of therapy, such as occlusive or pressure dressings. Large scars may be surgically excised but are likely to recur and may appear worse than the original lesions. To decrease the risk for recurrence, postoperative steroid injections or radiation therapy may be recommended.

These lesions may have a genetic component because they tend to run in families. If you are predisposed to keloid formation, you should avoid ear and body piercings and elective cosmetic surgical procedures because these may result in keloid formation. If you are having a surgical procedure, inform the surgeon that you are prone to keloids because they may change the way they close the incision site. Try to reduce the incidence of minor cuts of the skin because these may also progress into keloids. Take care in shaving and treat acne without causing injury to the skin. If cuts do occur, keep them clean and moist while they heal. This can be done by applying gentle emollients, such as Vaseline or Aquaphor, and covering the affected area with gauze, Telfa, or a bandage.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here